Wall Street opened on the low note following a hotter PCE reading supporting Fed’s cautious stance on sticking to the current level of interest rates. Nasdaq and S&P500 are down 0,35%, DJIA loses 0,45% and Russell 2000 trades 0,25% lower.
The Fed’s preferred inflation gauge showed prices rising more than expected in February, with core PCE up 0.4% from the prior month and 2.8% year-over-year, exceeding forecasts. Reading was driven mainly by price pressures in specialised services like finance, healthcare, insurance). Higher inflation may keep the Fed cautious on rate cuts, especially given the uncertainty over the true economic effect of subsequent tariffs coming into effect.
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile appPersonal spending rose 0.4%, missing estimates, following January’s surprise decline. Economists warn that rising prices and slowing consumption could dampen growth. The report follows the Fed’s decision to hold rates steady while lowering its 2025 growth forecast and raising inflation projections. Officials still anticipate two rate cuts this year.
Volatility currently observed in the U.S. Source: xStation5
US100 (D1)
US100 extends losses from yesterday, as “there’s no Tesla” to counterbalance the selloff of other Big Tech stocks. Amid Mag7 companies, only Nvidia trades higher (NVDA.US: +0.4%) on expected chip tariffs. RSI remains neutral, slightly below 50, while further price pressure below faster EMA30 (light purple) heralds a potential test of the support around 19,4K.
Source: xStation5
Company news:
-
Beam Therapeutics (BEAM.US) is up 1% after Bank of America upgrades it to buy, citing promising trial data for BEAM-302 in alpha-1 antitrypsin deficiency. Analyst sees it as a key value unlock. Beam also announced FDA clearance for its investigational drug, with more trial data expected in H2 2025.
-
CureVac (CVAC.US) jumps 10% after the European Patent Office upheld its mRNA patent in a legal dispute with BioNTech. Analysts call it a positive milestone, though an infringement ruling on July 1 remains key. A favorable ruling could lead to damages assessment proceedings.
-
Lexicon Pharmaceuticals surges 60% after securing an exclusive license deal with Novo Nordisk (NOVOB.DK) for obesity drug LX9851. The deal includes up to $1B in payments, with $75M in near-term milestones. Lexicon will complete pre-IND activities, while Novo Nordisk handles development and commercialization.
-
Lululemon (LULU.US) drops 14% after issuing weak guidance, fueling US growth concerns. Analysts cite sluggish American demand, margin pressures, and rising competition. Q1 revenue forecast of $2.34B–$2.36B missed estimates of $2.39B, and EPS guidance of $2.53–$2.58 fell short of the $2.78 estimate. Full-year EPS guidance of $14.95–$15.15 also missed the $15.38 consensus.
-
Nippon Steel and US Steel (X.US) are in talks to salvage their merger, with Nippon offering to raise its planned $2.7B factory investment to as much as $7B. The deal, facing political scrutiny, has been delayed again, now expected to close in Q2 2025.
-
Rocket Lab (RKLB.US) add 2.5% after being selected for the US Space Force’s $5.6B National Security Space Launch program. Citi calls it a positive surprise, noting earlier-than-expected inclusion. Rocket Lab plans to have three Neutron rockets ready in 2026 and five more in 2027.
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
